YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Effects of Piroxicam on Pharmacodynamics and Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats

피록시캄이 니페디핀의 약력학 및 약동학에 미치는 영향

  • 최기환 (식품의약품안전청 국립독성연구소) ;
  • 박인숙 (식품의약품안전청 국립독성연구소) ;
  • 김동섭 (식품의약품안전청 국립독성연구소) ;
  • 정혜주 (식품의약품안전청 국립독성연구소)
  • Published : 2000.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Because nonsteroidal anti-inflammatory drugs are reported to cause fluid retention and hypertension by inhibition of prostaglandin synthesis, the effects of piroxicam on pharmacodynamics and pharmacokinetics of nifedipine were studied in male spontaneously hypertensive rats. They received nifedipine (0.5 mg/kg) alone or combined with piroxicam (5 mg/kg) intravenously. Plasma levels norepinephrine, an index of sympathetic stimulation, were measured prior to each treatment and 5 min after drug administration. Changes in blood pressure were examined serially and blood samples for analysis of nifedipine were also taken for 6 hr following drug administration. Plasma nifedipine concentration were assayed by HPLC and pharmacokinetic parameters were calculated. Blood pressure was reduced (p<0.01), but plasma norepinephrine level was increased (p<0.05) by nifedipine administration. Anti-hypertensive effect of nifedipine was potentiated (p<0.05) by piroxicam coadministration, but effect of nifedipine on plasma norepinephrine level was not affected. In case of rats received nifedipine and piroxicam, plasma nifedipine concentrations were higher (p<0.05) than those from rats received nifedipine alone at 2,3,4,5 and 6 hours following drug administration. The area under the plasma concentration vs. time curve was increased (p<0.05), while the elimination rate constant was decreased (p<0.01) by piroxicam coadministration. No significant differences were observed in the plasma clearance, apparent volume of distribution and elimination half-life. Thus, piroxicam not only potentiated antihypertensive effect of nifedipine, but also altered nifedipine pharmacokinetics in the rats. It is concluded that the potentiation of nifedipine antihypertensive effect might correlate with the increment of its plasma concentration by piroxicam coadministration.

Keywords

References

  1. Arz-neimittelforschung v.26 no.7 Piroxicam, a novel anti-inflamatory agent Wiseman. E.H.;Chang. Y.H.;Lombardino. J.G.
  2. The pharmacological basis of therapeutics (8th ed) Gilman. A.G.;Rall. T.W.;Nies. A.S.;Taylor. P.
  3. Aust. NZ J. Med. v.12 Non-steroidal antiinflammatory drugs and blood pressure Mills. E.H.;Whitworth. J.A.;Andrews. J.;Kincaid-Smith. P.
  4. Pharmac. Ther. v.15 Prostagrandins and regulation of blood pressure. Clinical implications Sullivan. J.M.
  5. N. Engl. J. Med. v.310 Renal syndromes associated with nonsteroidal anti-inflammatory drugs D.M. Clive;J.S.;Stoff. J.S.
  6. Kidney Int. v.32 The clinical significance of inhibition of renal prostagrandin synthesis Patrono. C.;Dunn. M.J.
  7. Adv. Ther. v.2 Effect of sulindac, piroxicam and placebo on the hypotensive effect of propranolo in patients with mild to moderate essential hypertension Ebel. D.L.;Rhymer. A.R.;Stahl. E.
  8. Lancet v.i Effect of non-steroidal antiinflammatory drugs on control of hypertension by beta-blockers and diuretics Wong. D.G;Spence. J.D.;Lamki. L.;Freeman. D.;McDonald. J.W.D.
  9. Br. Med. J. v.281 Attenuation of hypotensive effects of propranolol and thiazide diuretics by indomethacin Qatkins. J.;Abbott. E.C.;Hensby. C.N.;Webster. J.;dollery. C.T
  10. J. Clin. Pharmacol. v.26 Effect of sulindac and piroxicam administration on the antihypertensive effect of propranolol Alvarez. C.R.;baez. M.A.;Weidler. D.J.
  11. Eur. J. Clin. Invest. v.14 Differential interaction of piroxicam and sulindac with the anti-hypertensive effect of propranolo Pugliese. F.;Simonetti. B.M.;Cinotte. G.A.;Ciabattoni. G.;Catella. F.;Vastano. S.;Ghidini. O.A.;Pierucci. A.
  12. J. Int. Med. Res. v.16 Effect of ibuprofen on blood pressure control by propranolol and bendrofluazide Davies. J.G.;Rawlins. D.C.;Busson. M.
  13. Clin. Chem. v.29 Measurement of nifedipine in plasma by gas-liquid chromatography and electron-capture detection Hamann. S.R.;McAllister. R.G.
  14. 카톨릭 대학교 의과대학 논문집 v.46 no.4 정상혈압 및 자연발생성 고혈압 흰쥐에서 혈압과 혈장 카테콜아민 농도에 대한 콜린에스테라제 억제약의 중추작용 김성윤;이상복
  15. J. Pharmacol. Exp. Ther. v.138 A study of the factors affecting the aluminum oxide-trihydroxyindol procedure for the analysis of catecholamine Anton. A.H.;Sayre. D.F.
  16. Life Sci. v.28 Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man Goldstein. D.S.;Feuerstein. G.;Izzo. J.L.Jr.;Kopin. I.J.;Kelser. H.R.
  17. Int. J. Clin. Pharmacol. Ther. Toxicol. v.29 no.9 Pharmacokinetics and pharmacodynamics of two commercial oral nifedipine products Shaheen. O.;Zmeili. S.;Al-Qussuois. Y.;Arafat. T.;Mouti. H.
  18. J. Pharmacol. Exp. Ther. v.249 no.2 Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat Boje. K.M.;Fung. H-L
  19. Drugs. v.30 Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy, in sdchaemic heart disease, hypertension and related cardiovascular disorders. Sorkin. E.M.;Clissold. S.P.;Brogden. R.N.
  20. Proceedings of the symposium held in Berlin New therapy of ischemic heart disease and hypertension. Kaltenbach and Neufeld 5th International Adalat(R) Symposium
  21. Calcium antagonism in heart and smooth muscle. Experimental facts and therapeutic prospects Fleckenstein. A.
  22. Eur. J. clin. Phamacol. v.23 The effects of nifedipine and hydralazine induced hypotension on sympathetic activity Murphy. M.B.;Scriven. A.J.;Brown. M.J.;Causon. R.;Dollery. C.T.
  23. Clin. Pharmacol. Ther. v.35 Nifedipine: Kinetics and dynamics in healthy subjects Kleinbloesem. C.H.;Van Brummelen. P.;Van de Linde. J.A.;Voogd. P.J.;Breimer. D.D.
  24. Eur. J. Clin. Phamacol. v.15 Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension Lederballe Pederson. O.;Mikkelsen. E.;Christensen. N.J.;Kornerup. H.J.;Pedersen. E.B.
  25. Am. J. Nephrol. v.SUP6 Calcium antagonists: Interaction in hypertension Salvetti. A.;Pedrinelli. R.;Magagna. A.;Stornello. M.;Scapellato. L.